Unituxin Disease Interactions

Dinutuximab can cause electrolytes abnormalities, including hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Electrolyte abnormalities should be corrected prior to initiating nilotinib and should be monitored daily during therapy.

Atypical hemolytic uremic syndrome in the absence of documented infection and resulting in renal insufficiency, electrolyte abnormalities, anemia, and hypertension can occur in patients treated with dinutuximab. Atypical hemolytic uremic syndrome has recurred following rechallenge with dinutuximab. Permanently discontinue therapy and institute supportive management for signs of hemolytic uremic syndrome.

Hypotension has been observed during therapy with dinutuximab. This drug should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension. It is recommended to administer required intravenous hydration prior to each infusion and to closely monitor blood pressure during treatment. Interruption or discontinuation of treatment might be necessary if systolic blood pressure is less than lower limit of normal for age, or if it decreases by more than 15% compared to baseline.

Myelosuppression has been reported during administration of dinutuximab. In a clinical study, severe thrombocytopenia, anemia, neutropenia occurred more frequently in patients treated with dinutuximab/13-cis-retinoic acid group compared to those treated with 13-cis-retinoic acid alone. Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression. Clinical monitoring of hematopoietic function is recommended during therapy.

Dinutuximab causes serious neurologic adverse reactions including, severe neuropathic pain, peripheral neuropathy, neurologic disorders of the eye, prolong urinary retention, and transverse myelitis. Discontinue treatment for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy. It might be necessary to permanently discontinue treatment in certain cases. Care should be exercised when prescribing this agent to patients at risk for neurotoxicity. It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.

The use of dinutuximab may cause reversible posterior leukoencephalopathy syndrome (RPLS). Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS. It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.